PA-2612

N/A

Report date: 2025/02/01 20:00:06

NME

Base Information

Drug NamePA-2612

Drug Alias Namealdose reductase inhibitor (Livwel)aldose reductase inhibitor (Livwel)aldose reductase inhibitor (Livwel)aldose reductase inhibitor (Livwel)PA-2612

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionAldose reductase inhibitors

TargetsAldose reductase

Therapy Area/IndicationsUveitisPulmonary Disease, Chronic ObstructiveAsthma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesLivwel Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesLivwel Therapeutics Inc

Active IndicationsN/A

Inactive IndicationsUveitisPulmonary Disease, Chronic ObstructiveAsthma

Other Information

ATC CodeN/A